Claims for Patent: 9,186,392

Summary for Patent: 9,186,392

Title:	Combination therapy
Abstract:	The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
Inventor(s):	Klein; Thomas (Radolfzell, DE), Grempler; Rolf (Birkenhard/Warthausen, DE), Mark; Michael (Biberach an der Riss, DE)
Assignee:	Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:	13/695,492
Patent Claims:	1. A method for maintaining a subject in a state of reduced weight after weight reducing treatment, said method comprising administering linagliptin to said subject, wherein the administration of linagliptin is carried out subsequent to the weight reducing treatment in order to maintain the reduced body weight or delay an increase in body weight in said subject. 2. The method according to claim 1, wherein the weight reducing treatment is selected from diet, exercise and/or treatment with an anti-obesity or weight reducing agent selected from the group consisting of a glucagon-like peptide-1 (GLP-1) receptor agonist, a lipase inhibitor which is orlistat or cetilistat, a cannabinoid receptor 1 antagonist, a melanocortin-4 (MC4) receptor agonist, a neuropeptide Y2-receptor (NPY2) antagonist, a 5-hydroxytryptamine 2C (5HT2c) receptor agonist, a Ghrelin antagonist, pancreatic peptide YY3-36 (Pyy 3-36), leptin, a diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitor, a noradrenaline-dopamine-5HT reuptake inhibitor, bupropion/naltrexone, bupropion/zonisamide, topiramate/phentermine, pramlintide/metreleptin, a melanin-concentrating hormone (MCH) antagonist, a cholecystokinin (CCK) inhibitor, a fatty acid synthase (FAS) inhibitor, an acetyl-CoA carboxylase (ACC) inhibitor, a stearoyl-CoA desaturase (SCD) inhibitor, a beta3 adrenoreceptor agonist, a microsomal triglyceride transfer protein (MTP) inhibitor, and amylin or an amylin analogue which is davalintide or pramlintide. 3. The method of claim 1, wherein the subject is an obesity patient prior to weight reducing treatment. 4. A method for maintaining a subject in a state of reduced weight after weight reducing treatment with a GLP-1 receptor agonist selected from exenatide, exenatide LAR, liraglutide, taspoglutide, semaglutide, albiglutide, lixisenatide and dulaglutide, said method comprising administering linagliptin to said subject wherein the administration of linagliptin is carried out subsequent to the weight reducing treatment with said GLP-1 receptor agonist in order to maintain the reduced body weight or delay an increase in body weight in said subject.

Details for Patent 9,186,392

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	February 24, 2014		2031-05-05
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	April 15, 2014		2031-05-05
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 18, 2014		2031-05-05
Eli Lilly And Company	TRULICITY	dulaglutide	Injection	125469	September 04, 2020		2031-05-05
Sanofi-aventis U.s. Llc	ADLYXIN	lixisenatide	Injection	208471	July 27, 2016		2031-05-05